Autophagy:自噬如何维持葡萄糖体内平衡

2017-12-26 海北 MedSci原创

巨自噬/自噬是一个从酵母到哺乳动物都高度保守的过程,其可以将不需要的细胞内容物递送到溶酶体或液泡,并进行降解。

巨自噬/自噬是一个从酵母到哺乳动物都高度保守的过程,其可以将不需要的细胞内容物递送到溶酶体或液泡,并进行降解。据报道,自噬对维持葡萄糖体内平衡至关重要。然而,至今为止,能量剥夺诱导自噬的机制尚不完善。

最近,来自清华大学的研究人员发现,最初被认定为DNA损伤传感器的Mec1 / ATR对于葡萄糖饥饿诱导的自噬是必不可少的。 Mec1被招募到线粒体中,而后其被活化的Snf1磷酸化,以响应葡萄糖饥饿。Mec1的磷酸化导致Snf1-Mec1-Atg1模块在线粒体上的组装,其能够进一步促进Atg1与Atg13的结合。此外,研究人员还发现线粒体呼吸是葡萄糖饥饿诱导的自噬所必须的,但不是由典型刺激引起的自噬所必须的。

因此,Snf1-Mec1-Atg1模块对于维持线粒体呼吸和调节葡萄糖饥饿诱导的自噬是必需的。


原始出处:

Cong Yi et al. Mitochondria: The hub of energy deprivation-induced autophagyAutophagy, 2017. doi: https://doi.org/10.1080/15548627.2017.1382785


本文系梅斯医学(MedSci)原创编译整理,转载需授权


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=277889, encodeId=d6f22e78893d, content=学习., beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDcVAydhtcpjiaxLrZD7Eb5YnKPgf7ypGpfyl7FflFyAenvQLbib6T0LPXIhXo9SPNPXYYFFJbEgykztwJ0HQ61I3F9GxIVKWsgQ/0, createdBy=f38d2052407, createdName=周周人, createdTime=Fri Jan 12 19:08:14 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275385, encodeId=1d292e538525, content=学习., beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDcVAydhtcpjiaxLrZD7Eb5YnKPgf7ypGpfyl7FflFyAenvQLbib6T0LPXIhXo9SPNPXYYFFJbEgykztwJ0HQ61I3F9GxIVKWsgQ/0, createdBy=f38d2052407, createdName=周周人, createdTime=Thu Jan 04 12:44:35 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=272647, encodeId=cc342e264738, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=b0041939716, createdName=hhh678, createdTime=Tue Dec 26 12:11:02 CST 2017, time=2017-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=272626, encodeId=465b2e262659, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Tue Dec 26 11:09:39 CST 2017, time=2017-12-26, status=1, ipAttribution=)]
    2018-01-12 周周人

    学习.

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=277889, encodeId=d6f22e78893d, content=学习., beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDcVAydhtcpjiaxLrZD7Eb5YnKPgf7ypGpfyl7FflFyAenvQLbib6T0LPXIhXo9SPNPXYYFFJbEgykztwJ0HQ61I3F9GxIVKWsgQ/0, createdBy=f38d2052407, createdName=周周人, createdTime=Fri Jan 12 19:08:14 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275385, encodeId=1d292e538525, content=学习., beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDcVAydhtcpjiaxLrZD7Eb5YnKPgf7ypGpfyl7FflFyAenvQLbib6T0LPXIhXo9SPNPXYYFFJbEgykztwJ0HQ61I3F9GxIVKWsgQ/0, createdBy=f38d2052407, createdName=周周人, createdTime=Thu Jan 04 12:44:35 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=272647, encodeId=cc342e264738, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=b0041939716, createdName=hhh678, createdTime=Tue Dec 26 12:11:02 CST 2017, time=2017-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=272626, encodeId=465b2e262659, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Tue Dec 26 11:09:39 CST 2017, time=2017-12-26, status=1, ipAttribution=)]
    2018-01-04 周周人

    学习.

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=277889, encodeId=d6f22e78893d, content=学习., beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDcVAydhtcpjiaxLrZD7Eb5YnKPgf7ypGpfyl7FflFyAenvQLbib6T0LPXIhXo9SPNPXYYFFJbEgykztwJ0HQ61I3F9GxIVKWsgQ/0, createdBy=f38d2052407, createdName=周周人, createdTime=Fri Jan 12 19:08:14 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275385, encodeId=1d292e538525, content=学习., beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDcVAydhtcpjiaxLrZD7Eb5YnKPgf7ypGpfyl7FflFyAenvQLbib6T0LPXIhXo9SPNPXYYFFJbEgykztwJ0HQ61I3F9GxIVKWsgQ/0, createdBy=f38d2052407, createdName=周周人, createdTime=Thu Jan 04 12:44:35 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=272647, encodeId=cc342e264738, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=b0041939716, createdName=hhh678, createdTime=Tue Dec 26 12:11:02 CST 2017, time=2017-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=272626, encodeId=465b2e262659, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Tue Dec 26 11:09:39 CST 2017, time=2017-12-26, status=1, ipAttribution=)]
    2017-12-26 hhh678

    henhao

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=277889, encodeId=d6f22e78893d, content=学习., beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDcVAydhtcpjiaxLrZD7Eb5YnKPgf7ypGpfyl7FflFyAenvQLbib6T0LPXIhXo9SPNPXYYFFJbEgykztwJ0HQ61I3F9GxIVKWsgQ/0, createdBy=f38d2052407, createdName=周周人, createdTime=Fri Jan 12 19:08:14 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275385, encodeId=1d292e538525, content=学习., beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDcVAydhtcpjiaxLrZD7Eb5YnKPgf7ypGpfyl7FflFyAenvQLbib6T0LPXIhXo9SPNPXYYFFJbEgykztwJ0HQ61I3F9GxIVKWsgQ/0, createdBy=f38d2052407, createdName=周周人, createdTime=Thu Jan 04 12:44:35 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=272647, encodeId=cc342e264738, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=b0041939716, createdName=hhh678, createdTime=Tue Dec 26 12:11:02 CST 2017, time=2017-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=272626, encodeId=465b2e262659, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Tue Dec 26 11:09:39 CST 2017, time=2017-12-26, status=1, ipAttribution=)]
    2017-12-26 sunfeifeiyang

    学习

    0

相关资讯

Autophagy:自噬可以在肝癌中调节糖酵解

细胞自噬的受损和高水平的糖酵解在肝癌中普遍存在。然而,至今为止,自噬与糖酵解代谢之间是否存在调控关系尚不清楚。

Autophagy:抗癌药物博来霉素为何会导致肺纤维化?

博莱霉素是一种有效的临床抗癌药物,用于治疗生殖细胞肿瘤,淋巴瘤和鳞状细胞癌。不幸的是,博莱霉素的治疗效果受到肺纤维化发展的严重阻碍。

Autophagy:自噬可以调节黑色素瘤发展

黑色素瘤是人类最危险的癌症之一,死亡率极高。黑色素瘤的发病机制至今尚未完全阐明。近来,已经发现失调的巨自噬/自噬在调节不同阶段的黑素瘤生长中发挥重要但不一致的作用,但其调节机制不清楚。

Autophagy:华人科学家阐述自噬如何介导肝纤维化

细菌移位和脂多糖(LPS)泄漏发生在动物肝纤维化模型的非常早期。来自中山大学的研究人员研究了LPS在肝星状细胞(HSC)激活中的作用,以及体内和体外的潜在机制。

Autophagy:自噬蛋白影响大脑发育

我们已知哺乳动物ULK1(unc-51样激酶1)和ULK2,秀丽隐杆线虫UNC-51,和黑腹果蝇Atg1是丝氨酸/苏氨酸激酶,其可以响应各种类型的细胞应激,进而调节细胞自噬通量。

Autophagy:RAS突变如何促进癌症发展

已有的研究显示,RAS GTPase的活化突变有助于许多癌症的发展,包括结直肠癌。但是到目前为止,由于对RAS信号传导机制认识的不足,对于携带突变RAS的癌症治疗的开发尝试并不成功。